The chemotherapeutic agent VP16 increases the stability of HB-EGF mRNA by a mechanism involving the 3′-UTR

Experimental Cell Research

Volumn 312, Issue 18, 2006, Pages 3651-3658

  Sorensen, Boe S ^a   Ornskov, Dorthe ^a   Nexo, Ebba ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

3 UTR; EGF system; HB EGF; mRNA stability

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; DACTINOMYCIN; ETOPOSIDE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LUCIFERASE; MESSENGER RNA; NUCLEOTIDE;

3' UNTRANSLATED REGION; ARTICLE; DOSE RESPONSE; GENE INSERTION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA STABILITY; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER;

EID: 33749117355     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.08.007     Document Type: Article

References (31)

1. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19 (2000) 3159-3167
2. Harris R.C., Chung E., and Coffey R.J. EGF receptor ligands. Exp. Cell Res. 284 (2003) 2-13
3. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284 (2003) 14-30
4. Holbro T., Civenni G., and Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284 (2003) 99-110
5. Gilmore A.P., Valentijn A.J., Wang P., Ranger A.M., Bundred N., O'Hare M.J., Wakeling A., Korsmeyer S.J., and Streuli C.H. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 277 (2002) 27643-27650
6. Yu D.H., Tian J., Liu B.L., Yao J., Tan M., McDonnell T.J., and Hung M.C. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21(Cip1), which inhibits p34(Cdc2) kinase. Mol. Cell 2 (1998) 581-591
7. Sorensen B.S., Torring N., Bor M.V., and Nexo E. The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol. Cell. Biochem. 260 (2004) 129-135
8. Fortune J.M., and Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 64 64 (2000) 221-253
9. Horikawa M., Higashiyama S., Nomura S., Kitamura Y., Ishikawa M., and Taniguchi N. Upregulation of endogenous heparin-binding EGF-like growth factor and its role as a survival factor in skeletal myotubes. FEBS Lett. 459 (1999) 100-104
10. Lin J., Hutchinson L., Gaston S.M., Raab G., and Freeman M.R. BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J. Biol. Chem. 276 (2001) 30127-30132
11. Brennan C.M., and Steitz J.A. HuR and mRNA stability. Cell. Mol. Life Sci. 58 (2001) 266-277
12. Kaneto H., Miyagawa J., Kajimoto Y., Yamamoto K., Watada H., Umayahara Y., Hanafusa T., Matsuzawa Y., Yamasaki Y., Higashiyama S., and Taniguchi N. Expression of heparin-binding epidermal growth factor-like growth factor during pancreas development-A potential role of PDX-1 in transcriptional activation. J. Biol. Chem. 272 (1997) 29137-29143
13. Christensen B., Kieler J., Vilien M., Don P., Wang C.Y., and Wolf H. A classification of human urothelial cells propagated in vitro. Anticancer Res. 4 (1984) 319-337
14. Balmer L.A., Beveridge D.J., Jazayeri J.A., Thomson A.M., Walker C.E., and Leedman P.J. Identification of a novel AU-rich element in the 3′ untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding proteins. Mol. Cell. Biol. 21 (2001) 2070-2084
15. Ornskov D., Nexo E., and Sorensen B.S. Real-time polymerase chain reaction is a sensitive and precise method for quantifying transcription from reporter plasmids. Scand. J. Clin. Lab. Invest. 64 (2004) 723-728
16. Torring N., Jorgensen P.E., Sorensen B.S., and Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res. 20 (2000) 91-95
17. Christensen M.E., Engbaek F., Therkildsen M.H., Bretlau P., and Nexo E. A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations. Br. J. Cancer 72 (1995) 1487-1493
18. Lin J., Adam R.M., Santiestevan E., and Freeman M.R. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59 (1999) 2891-2897
19. Gibson S., Tu S., Oyer R., Anderson S.M., and Johnson G.L. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem. 274 (1999) 17612-17618
20. Takemura T., Kondo S., Homma T., Sakai M., and Harris R.C. The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells. J. Biol. Chem. 272 (1997) 31036-31042
21. M. Munk, A.A. Memon, E. Nexo, B.S. Sorensen, Inhibition of the EGF receptor in bladder cancer cells treated with the DNA damaging drug VP16 markedly increase apoptosis. BJU int. (in press).
22. Subbaramaiah K., Marmo T.P., Dixon D.A., and Dannenberg A.J. Regulation of cyclooxgenase-2 mRNA stability by taxanes-Evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem. 278 (2003) 37637-37647
23. Wang W.G., Furneaux H., Cheng H.M., Caldwell M.C., Hutter D., Liu Y.S., Holbrook N., and Gorospe M. HuR regulates p21 mRNA stabilization by UV light. Mol. Cell. Biol. 20 (2000) 760-769
24. de Silanes I.L., Fan J.S., Yang X.L., Zonderman A.B., Potapova O., Pizer E.S., and Gorospe M. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 22 (2003) 7146-7154
25. Dixon D.A., Kaplan C.D., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Post-transcriptional control of cyclooxygenase-2 gene expression-The role of the 3′-untranslated region. J. Biol. Chem. 275 (2000) 11750-11757
26. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 108 (2001) 1657-1665
27. Jain R.G., Andrews L.G., McGowan K.M., Pekala P.H., and Keene J.D. Ectopic expression of Hel-N1, an RNA-binding protein, increases glucose transporter (GLUT1) expression in 3T3-L1 adipocytes. Mol. Cell. Biol. 17 (1997) 954-962
28. Carballo E., Lai W.S., and Blackshear P.J. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281 (1998) 1001-1005
29. Gherzi R., Lee K.Y., Briata P., Wegmuller D., Moroni C., Karin M., and Chen C.Y. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol. Cell 14 (2004) 571-583
30. Sarkar B., Xi Q.R., He C., and Schneider R.J. Selective degradation of AU-rich mRNAs promoted by the p37 AUF1 protein isoform. Mol. Cell. Biol. 23 (2003) 6685-6693
31. Stoecklin G., Colombi M., Raineri I., Leuenberger S., Mallaun M., Schmidlin M., Gross B., Lu M., Kitamura T., and Moroni C. Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover. EMBO J. 21 (2002) 4709-4718